Human NPC1L1 expression is positively regulated by PPARα

Pharmaceutical Research

Volumn 28, Issue 2, 2011, Pages 405-412

  Iwayanagi, Yuki ^a   Takada, Tappei ^a   Tomura, Fumiya ^a   Yamanashi, Yoshihide ^a   Terada, Tomohiro ^b,c   Inui, Ken Ichi ^b,d   Suzuki, Hiroshi ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE HOSPITAL   (Japan)

^d KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

cholesterol; ezetimibe; fenofibrate; fibrates; transporter

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 4ALPHA; MESSENGER RNA; NEIMANN PICK C1 LIKE 1 PROTEIN; NPC1L1 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; CELL STRAIN HEPG2; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DNA FLANKING REGION; FATTY ACID METABOLISM; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE CONSTRUCT; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSFECTION; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; REPORTER GENE; TRANSACTIVATION; TRANSCRIPTION REGULATION;

AZETIDINES; CHOLESTEROL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENTEROCYTES; FENOFIBRATE; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MEMBRANE PROTEINS; NIEMANN-PICK DISEASES; PPAR ALPHA; PPAR GAMMA; PROTEIN BINDING; RESPONSE ELEMENTS;

EID: 79952490607     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0294-4     Document Type: Article

References (33)

1. Altmann SW, Davis Jr HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201-4. (Pubitemid 38233587)
2. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem. 2005;280(13):12710-20.
3. Davis Jr HR, Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem. 2004;279(32):33586-92. (Pubitemid 39063007)
4. Yamanashi Y, Takada T, Suzuki H. Niemann-Pick C1-like 1 overexpression facilitates ezetimibe-sensitive cholesterol and beta-sitosterol uptake in CaCo-2 cells. J Pharmacol Exp Ther. 2007;320(2):559-64. (Pubitemid 46147934)
5. Narushima K, Takada T, Yamanashi Y, Suzuki H. Niemann-pick C1-like 1 mediates alpha-tocopherol transport. Mol Pharmacol. 2008;74(1):42-9. (Pubitemid 351872157)
6. Yamanashi Y, Takada T, Suzuki H. In-vitro characterization of the six clustered variants of NPC1L1 observed in cholesterol low absorbers. Pharmacogenet Genomics. 2009;19(11):884-92.
7. Takada T, Suzuki H. Molecular mechanisms of membrane transport of vitamin E. Mol Nutr Food Res. 2010;54(5):616-22.
8. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA. 2005;102(23):8132-7. (Pubitemid 40800055)
9. Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA, et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007;117(7):1968-78. (Pubitemid 47036331)
10. Alrefai WA, Annaba F, Sarwar Z, Dwivedi A, Saksena S, Singla A, et al. Modulation of human Niemann-Pick C1-like 1 gene expression by sterol: role of sterol regulatory element binding protein 2. Am J Physiol Gastrointest Liver Physiol. 2007;292(1):G369-76.
11. Iwayanagi Y, Takada T, Suzuki H. HNF4alpha is a crucial modulator of the cholesterol-dependent regulation of NPC1L1. Pharm Res. 2008;25(5):1134-41.
12. van der Veen JN, Kruit JK, Havinga R, Baller JF, Chimini G, Lestavel S, et al. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res. 2005;46(3):526-34. (Pubitemid 43109789)
13. Vrins CL, van der Velde AE, van den Oever K, Levels JH, Huet S, Oude Elferink RP, et al. Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux. J Lipid Res. 2009;50(10):2046-54.
14. Duval C, Touche V, Tailleux A, Fruchart JC, Fievet C, Clavey V, et al. Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem Biophys Res Commun. 2006;340(4):1259-63. (Pubitemid 43083413)
15. Lalloyer F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, et al. The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2006;26(12):2731-7.
16. Ratliff EP, Gutierrez A, Davis RA. Transgenic expression of CYP7A1 in LDL receptor-deficient mice blocks diet-induced hypercholesterolemia. J Lipid Res. 2006;47(7):1513-20. (Pubitemid 44079905)
17. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 1995;96(2):741-50.
18. Valasek MA, Clarke SL, Repa JJ. Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. J Lipid Res. 2007;48(12):2725-35. (Pubitemid 350272857)
19. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA. 1993;90(6):2160-4. (Pubitemid 23078585)
20. Flavell DM, Ireland H, Stephens JW, Hawe E, Acharya J, Mather H, et al. Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes. 2005;54(2):582-6.
21. Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M. Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes. 2007;56(4):1181-6. (Pubitemid 46525087)
22. Lally S, Tan CY, Owens D, Tomkin GH. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia. 2006;49(5):1008-16.
23. Lally SE, Owens D, Tomkin GH. Sitosterol and cholesterol in chylomicrons of type 2 diabetic and non-diabetic subjects: the relationship with ATP binding cassette proteins G5 and G8 and Niemann-Pick C1-like 1 mRNA. Diabetologia. 2007;50(1):217-9. (Pubitemid 46035872)
24. Okuwaki M, Takada T, Iwayanagi Y, Koh S, Kariya Y, Fujii H, et al. LXR alpha transactivates mouse organic solute transporter alpha and beta via IR-1 elements shared with FXR. Pharm Res. 2007;24(2):390-8. (Pubitemid 46072198)
25. Koh S, Takada T, Kukuu I, Suzuki H. FIC1-mediated stimulation of FXR activity is decreased with PFIC1 mutations in HepG2 cells. J Gastroenterol. 2009;44(6):592-600.
26. Latruffe N, Cherkaoui Malki M, Nicolas-Frances V, Clemencet MC, Jannin B, Berlot JP. Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases. Biochem Pharmacol. 2000;60(8):1027-32.
27. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006;116(3):615-22. (Pubitemid 43326866)
28. Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR, et al. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson. J Biol Chem. 2001;276(34):31521-7.
29. Farnier M, Freeman MW, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J. 2005;26(9):897-905.
30. McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson G, et al. Safety and efficacy of long-term coadministration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol. 2006;47(8):1584-7.
31. Montoudis A, Seidman E, Boudreau F, Beaulieu JF, Menard D, Elchebly M, et al. Intestinal fatty acid binding protein regulates mitochondrion {beta}-oxidation and cholesterol uptake. J Lipid Res. 2008;49(5):961-72.
32. Drover VA, Nguyen DV, Bastie CC, Darlington YF, Abumrad NA, Pessin JE, et al. CD36 mediates both cellular uptake of very long chain fatty acids and their intestinal absorption in mice. J Biol Chem. 2008;283(19):13108-15.
33. Nassir F, Wilson B, Han X, Gross RW, Abumrad NA. CD36 is important for fatty acid and cholesterol uptake by the proximal but not distal intestine. J Biol Chem. 2007;282(27):19493-501. (Pubitemid 47100088)